Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum

被引:7
作者
Tamoto, Akihiro [1 ]
Yashima, Kazuo [1 ]
Hosoda, Kohei [1 ]
Yamamoto, Sohei [1 ]
Kawata, Soichiro [1 ]
Ikebuchi, Yuichiro [1 ]
Matsumoto, Kazuya [1 ]
Kawaguchi, Koichiro [1 ]
Harada, Kenichi [1 ]
Murawaki, Yoshikazu [1 ]
Isomoto, Hajime [1 ]
机构
[1] Tottori Univ, Div Med & Clin Sci, Fac Med, 36-1 Nishicho, Yonago, Tottori 6838504, Japan
关键词
Fragile Histidine Triad; cyclooxygenase-2; serrated pathway; sessile serrated adenoma/polyp; endoscopic resection; ISLAND METHYLATOR PHENOTYPE; REDUCED FHIT EXPRESSION; CYCLOOXYGENASE-2; EXPRESSION; CPG ISLAND; MICROSATELLITE INSTABILITY; CLINICAL-SIGNIFICANCE; CANCER; CARCINOMA; ADENOMAS; COX-2;
D O I
10.3892/ol.2017.6634
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The adenoma-carcinoma sequence (ACS) and the serrated pathway are two distinct developmental routes leading to the formation of colorectal carcinoma (CRC). However, the mechanism triggered by the serrated pathway remains unclear. Therefore, to clarify the molecular and clinicopathological characteristics of the serrated tumorigenic pathway, immunohistochemistry was used to examine the expression of Fragile Histidine Triad (FHIT), cyclooxygenase-2 (COX-2), MutL homolog 1 (MLH1), MutS protein homolog 2 (MSH2) and P53 in endoscopically resected samples of 62 serrated polyps. These samples included 20 hyperplastic polyps (HPs), 16 traditional serrated adenomas (TSAs), 26 sessile serrated adenoma/polyps (SSA/Ps), 20 non-serrated adenomas, 20 carcinoma in adenomas (CIAs) and 18 early pure CRCs without any adenoma component (EPCs). FHIT expression was markedly reduced or absent in 50% of TSA samples, 92.3% of SSA/Ps and 44% of EPCs, but only rarely in HPs, non-serrated adenomas and CIAs. COX-2 expression was more common in non-serrated adenomas compared with in serrated polyps, and was present in 25 and 3.2% of the cases respectively (P<0.01). Furthermore, COX-2 expression was more frequent in CIAs (60%) compared with in EPCs (22.2%; P < 0.05). The incidence of negative COX-2 expression was higher in FHIT-negative SSA/Ps compared with in FHIT-positive SSA/Ps (P=0.08). A total of 16.7% of EPC samples and 11.5% of SSA/Ps demonstrated a loss of MLH1/MSH2 expression, but none of the other tumor types did. P53 overexpression was significantly increased in EPC (77.8%) and CIA (60%) samples compared with in HP (0%), TSA (6.6%), SSA/P (0%) and non-serrated adenoma (10%) samples (P<0.01). These findings demonstrated that there are different expression patterns between the serrated pathway and ACS, indicating that aberrant FHIT and inhibited COX-2 expression may be associated with serrated tumorigenesis. In addition, this data indicated that EPC may contain tumors derived from the serrated pathway as well as ACS.
引用
收藏
页码:3683 / 3688
页数:6
相关论文
共 38 条
[1]   Reduced FHIT Expression Is Associated with Mismatch Repair Deficient and High CpG Island Methylator Phenotype Colorectal Cancer [J].
Al-Temaimi, Rabeah Abbas ;
Jacob, Sindhu ;
Al-Ali, Waleed ;
Thomas, Diana Ann ;
Al-Mulla, Fahd .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2013, 61 (09) :627-638
[2]   Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma [J].
Andachi, H ;
Yashima, K ;
Koda, M ;
Kawaguchi, K ;
Kitamura, A ;
Hosoda, A ;
Kishimoto, Y ;
Shiota, G ;
Ito, H ;
Makino, M ;
Kaibara, N ;
Kawasaki, H ;
Murawaki, Y .
BRITISH JOURNAL OF CANCER, 2002, 87 (04) :441-445
[3]  
[Anonymous], JAP GEN RUL CLIN PAT
[4]  
[Anonymous], BR J CANC
[5]  
[Anonymous], CANCER
[6]   Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum [J].
Arao, J ;
Sano, Y ;
Fujii, T ;
Kato, S ;
Fu, KI ;
Yoshino, T ;
Ochiai, A ;
Fujimori, T ;
Yoshida, S .
DISEASES OF THE COLON & RECTUM, 2001, 44 (09) :1319-1323
[7]   The serrated pathway to colorectal carcinoma: current concepts and challenges [J].
Bettington, Mark ;
Walker, Neal ;
Clouston, Andrew ;
Brown, Ian ;
Leggett, Barbara ;
Whitehall, Vicki .
HISTOPATHOLOGY, 2013, 62 (03) :367-386
[8]   COX-2: A molecular target for colorectal cancer prevention [J].
Brown, JR ;
DuBois, RN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2840-2855
[9]   Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency [J].
Castells, A ;
Payá, A ;
Alenda, C ;
Rodríguez-Moranta, F ;
Agrelo, R ;
Andreu, M ;
Piñol, V ;
Castellví-Bel, S ;
Jover, R ;
Llor, X ;
Pons, E ;
Elizalde, JI ;
Bessa, X ;
Alcedo, J ;
Saló, J ;
Medina, E ;
Naranjo, A ;
Esteller, M ;
Piqué, JM .
CLINICAL CANCER RESEARCH, 2006, 12 (06) :1686-1692
[10]  
Cunningham JM, 1998, CANCER RES, V58, P3455